CClinicalTrials.gg
CompletedNCT04186858Updated Feb 5, 2020

Assessment of Levels of Intracellular Cytokines and Markers in Cells Recovered From the Anterior Eye (Phase 4)

An observational study in Impression Cytology, sponsored by Johnson & Johnson Vision Care, Inc.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-05.

Sponsored by Johnson & Johnson Vision Care, Inc. · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
22
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a single-visit, non-randomized, bilateral, cross-sectional study. In a pre-screening assessment, potential subjects will be invited to complete a web-based questionnaire that is validated to determine symptomatic vs asymptomatic contact lens wearers. Results of this questionnaire will be used to determine whether subjects are eligible to proceed to Visit 1. During Visit 1, cell samples will be collected from the front surface of the subject's eyes.

02

Conditions studied

  • Impression Cytology
03

In context

Lead sponsor

Johnson & Johnson Vision Care, Inc. is the lead sponsor of 220 studies on the registry; 2 are open to participants now.

Of its 110 completed or terminated interventional studies of FDA-regulated products, 101 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Eligible subjects aged 18 years and above with normal healthy eyes will be recruited for this work.

Inclusion criteria

  • Potential subjects must satisfy all of the following criteria to be enrolled in the study:

    1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form
    2. Appear able and willing to adhere to the instructions set forth in this clinical protocol.
    3. Be between 18 and 45 years of age (inclusive) at the time of screening
    4. They have worn the same brand of soft contact lenses for at least the previous three months.
    5. They agree not to participate in other clinical research trials for the duration of this study.
    6. In a pre-study screening assessment, they must have a CLDEQ-8 score of 10 or less (asymptomatic group) or 20 or higher (symptomatic group).
    7. They possess a wearable pair of distance glasses and agree to bring these to the study visit (if needed for distance vision correction).
    8. They can attain a high contrast logMAR visual acuity of 0.20 or better in their habitual contact lenses.
    9. Their habitual contact lenses fit satisfactorily.

Exclusion criteria

Exclusion Criteria:

  • Potential subjects who meet any of the following criteria will be excluded from participating in the study:

    1. Currently pregnant or lactating
    2. Any systemic disease (e.g., Sjögren's Syndrome), allergies, infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive diseases (e.g., HIV), autoimmune disease (e.g. rheumatoid arthritis), or other diseases, by self-report, which are known to interfere with contact lens wear and/or participation in the study
    3. They have an ocular disorder which would normally contraindicate contact lens wear.
    4. They have had cataract surgery.
    5. They have had corneal refractive surgery.
    6. They have any corneal distortion resulting from previous hard or rigid lens wear or have keratoconus.
    7. They have taken part in any other contact lens or care solution clinical trial research, within two weeks prior to starting this study.
    8. They are regularly (once per day or more) using oral or inhaled steroids or anti-inflammatory medications.
    9. They are using any topical medications such as eye drops or ointments.
    10. History of allergic reaction to sodium fluorescein or topical anesthetic.
    11. Use of systemic medications (e.g., chronic steroid use) that are known to interfere with contact lens wear
    12. Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).
    13. They have Grade 3 or greater of any of the following ocular surface signs: corneal edema, corneal vascularization, corneal staining (white light evaluation), tarsal conjunctival changes or any other abnormality which would normally contraindicate contact lens wear.
    14. Any active ocular infection or inflammation.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
22 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Symptomatic

    Based on the score of the questionnaire, eligible subjects will be placed in the Symptomatic group where cell samples will be collected from the front surface of the subject's eyes.

  • Asymptomatic

    Based on the score of the questionnaire, eligible subjects will be placed in the Asymptomatic group where cell samples will be collected from the front surface of the subject's eyes.

06

What researchers measure

Primary outcomes

  1. Number of Cells

    The frequency count of cells will be summarized within the category

    Time frame: ~6 hours of contact lens wear time

  2. Types of Cells

    The percentage of types of cells will be summarized within the category.

    Time frame: ~6 hours of contact lens wear time

07

Study locations

1 site
  • Eurolens Research - The University of Manchester
    Manchester, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04186858
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Responsible party
Sponsor
First posted
Dec 5, 2019
Start date
Nov 12, 2019
Primary completion
Jan 9, 2020
Completion
Jan 9, 2020
Last update
Feb 5, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion